Company Overview

Oramed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered therapeutic proteins. The company operates within the biotechnology and pharmaceuticals industries, with a primary emphasis on treatments for metabolic and endocrine diseases. Its core objective is to replace injectable therapies with oral alternatives by leveraging proprietary drug delivery technology designed to protect proteins from degradation in the gastrointestinal tract.

The company’s principal product candidate is ORMD-0801, an oral insulin capsule developed for the treatment of diabetes, which has been the primary driver of research spending and strategic focus. Oramed also developed ORMD-0901, an oral GLP-1 analog candidate, though this program has been deprioritized relative to insulin. Founded in 2006, Oramed evolved from early academic research into a publicly traded clinical-stage company, completing its initial public offering in 2013 and subsequently advancing its oral insulin program through multiple Phase 2 and Phase 3 clinical trials.

Business Operations

Oramed’s operations are centered on drug development rather than commercialization, and the company currently does not generate material product revenue. Its activities are organized around a single operating segment focused on the research and development of oral drug delivery systems for proteins, with ORMD-0801 representing the core asset. Revenue, when present, has historically consisted of collaboration payments, grants, or milestone-related income rather than recurring sales.

The company conducts clinical trials and regulatory activities primarily through outsourced contract research organizations while retaining control over its proprietary oral delivery technology. Oramed operates through its wholly owned subsidiary Oramed Ltd., which houses much of its research and development activity. The company has also entered into strategic collaborations and regional licensing discussions at various times, though no large-scale commercial partnership for insulin has been finalized based on publicly available disclosures.

Strategic Position & Investments

Oramed’s strategic direction is focused on advancing oral insulin toward regulatory approval while managing development risk through clinical trial design and cost control. A key strategic initiative in recent years has been the evaluation of alternative development pathways and geographic markets following mixed Phase 3 trial results for ORMD-0801, including reassessing dosing protocols and patient subpopulations.

The company has made targeted investments in manufacturing process development and intellectual property related to oral protein delivery. Oramed has also explored strategic alternatives, including partnerships and potential spin-offs, to maximize the value of its technology platform. Beyond insulin, the company maintains a portfolio of early-stage oral protein candidates, though these remain secondary to its flagship program.

Geographic Footprint

Oramed is headquartered in Israel, with its principal executive offices and research operations located in Jerusalem. The company is incorporated in Delaware, reflecting its status as a U.S.-listed public company, and its shares trade on the NASDAQ under the ticker ORMP. Clinical and regulatory activities span multiple regions, including North America, Europe, and Asia, depending on trial design and regulatory requirements.

The company’s international footprint is primarily operational rather than commercial, relying on global clinical trial sites and external partners. While Oramed does not maintain a broad commercial presence across continents, its development programs are intended for global markets, particularly regions with high diabetes prevalence.

Leadership & Governance

Oramed was founded by Nadav Kidron, who has played a central role in shaping the company’s scientific and strategic direction since inception. The leadership team emphasizes long-term innovation in drug delivery technology and maintains a governance structure typical of a clinical-stage biotechnology company, with oversight focused on capital allocation, clinical risk management, and regulatory strategy.

Key executives include:

• Nadav Kidron – Chief Executive Officer
• Dr. Miriam Kidron – Chief Scientific Officer
• Elad Kidron – Chief Business Officer
• Dor Gonen – Chief Financial Officer

The company’s board and executive leadership collectively guide its strategy with an emphasis on advancing oral biologics, maintaining intellectual property protection, and preserving financial flexibility during extended development timelines.